Social media responses to the approval of lecanemab in Japan: sentiment analysis

Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Tetsuaki Arai, Takeshi Iwatsubo · 2025

Read Social media responses to the approval of lecanemab in Japan: sentiment analysis by Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Tetsuaki Arai, Takeshi Iwatsubo (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716011.txt.

Description

Kenichiro Sato and five co-authors study how the Japanese public reacted online when the Alzheimer's drug lecanemab was approved in Japan, in this 2025 paper. The drug won approval in the United States in July 2023 and in Japan two months later. Online opinion was mixed, with debate over how well it works, its side effects, and its cost.

The team collected 478 posts from X and Facebook in the two weeks after approval and used an AI tool to sort them by tone. About forty-four percent were negative, thirty percent positive, and the rest neutral. Worry about the drug's effect on society drove most negative posts, and medical workers were more negative than others. The authors say drug makers and officials should tailor how they explain such treatments.

Catalog record

CREATORKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Tetsuaki Arai, Takeshi Iwatsubo
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11716011

Browse the full library · About the Tower of Babel